494 related articles for article (PubMed ID: 33113965)
1. Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.
Fania L; Didona D; Morese R; Campana I; Coco V; Di Pietro FR; Ricci F; Pallotta S; Candi E; Abeni D; Dellambra E
Biomedicines; 2020 Oct; 8(11):. PubMed ID: 33113965
[TBL] [Abstract][Full Text] [Related]
2. [What is new in basal cell carcinoma?].
Heppt M; von Braunmühl T; Berking C
Hautarzt; 2016 Nov; 67(11):876-883. PubMed ID: 27654826
[TBL] [Abstract][Full Text] [Related]
3. Basal cell carcinoma: Comprehensive clinical and histopathological aspects, novel imaging tools and therapeutic approaches (Review).
Niculet E; Craescu M; Rebegea L; Bobeica C; Nastase F; Lupasteanu G; Stan DJ; Chioncel V; Anghel L; Lungu M; Tatu AL
Exp Ther Med; 2022 Jan; 23(1):60. PubMed ID: 34917186
[TBL] [Abstract][Full Text] [Related]
4. Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma.
Doan HQ; Silapunt S; Migden MR
Onco Targets Ther; 2016; 9():5671-5678. PubMed ID: 27695345
[TBL] [Abstract][Full Text] [Related]
5. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
[TBL] [Abstract][Full Text] [Related]
6. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma.
Doan HQ; Chen L; Nawas Z; Lee HH; Silapunt S; Migden M
Oncotarget; 2021 Sep; 12(20):2089-2100. PubMed ID: 34611482
[TBL] [Abstract][Full Text] [Related]
7. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
[TBL] [Abstract][Full Text] [Related]
8. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors.
Bossi P; Ascierto PA; Basset-Seguin N; Dreno B; Dummer R; Hauschild A; Mohr P; Kaufmann R; Pellacani G; Puig S; Moreno-Ramírez D; Robert C; Stratigos A; Gutzmer R; Queirolo P; Quaglino P; Peris K
Crit Rev Oncol Hematol; 2023 Sep; 189():104066. PubMed ID: 37442495
[TBL] [Abstract][Full Text] [Related]
9. Beyond Mohs surgery and excisions: A focused review of treatment options for subtypes of basal cell carcinoma.
Altun E; Schwartzman G; Cartron AM; Khachemoune A
Dermatol Ther; 2021 Jan; 34(1):e14476. PubMed ID: 33125804
[TBL] [Abstract][Full Text] [Related]
10. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
12. Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors.
Fecher LA; Sharfman WH
Biologics; 2015; 9():129-40. PubMed ID: 26604681
[TBL] [Abstract][Full Text] [Related]
13. Emerging trends in the treatment of advanced basal cell carcinoma.
Migden MR; Chang ALS; Dirix L; Stratigos AJ; Lear JT
Cancer Treat Rev; 2018 Mar; 64():1-10. PubMed ID: 29407368
[TBL] [Abstract][Full Text] [Related]
14. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
Mathis J; Doerr T; Lin E; Ibrahim SF
Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
[TBL] [Abstract][Full Text] [Related]
15. [Not Available].
Basset-Seguin N
Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
[TBL] [Abstract][Full Text] [Related]
16. Sonidegib for the Treatment of Advanced Basal Cell Carcinoma.
Brancaccio G; Pea F; Moscarella E; Argenziano G
Front Oncol; 2020; 10():582866. PubMed ID: 33194718
[TBL] [Abstract][Full Text] [Related]
17. Hedgehog Pathway Inhibitors and Their Utility in Basal Cell Carcinoma: A Comprehensive Review of Current Evidence.
Tay EY; Teoh YL; Yeo MS
Dermatol Ther (Heidelb); 2019 Mar; 9(1):33-49. PubMed ID: 30539424
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma.
Yin VT; Esmaeli B
Curr Pharm Des; 2017; 23(4):655-659. PubMed ID: 27928965
[TBL] [Abstract][Full Text] [Related]
19. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
Leavitt E; Lask G; Martin S
Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
[TBL] [Abstract][Full Text] [Related]
20. Hedgehog Pathway Inhibitors: Clinical Implications and Resistance in the Treatment of Basal Cell Carcinoma.
Habashy S; Jafri A; Osman HO; Thomas NE; Udekwe S; Heindl SE
Cureus; 2021 Mar; 13(3):e13859. PubMed ID: 33754119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
